Search

Your search keyword '"Rosina F"' showing total 98 results
Start Over Author "Rosina F" Journal journal of hepatology
98 results on '"Rosina F"'

3. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Author

Karampatou, Aimilia, primary, Han, Xue, additional, Kondili, Loreta A., additional, Taliani, Gloria, additional, Ciancio, Alessia, additional, Morisco, Filomena, additional, Critelli, Rosina Maria, additional, Baraldi, Enrica, additional, Bernabucci, Veronica, additional, Troshina, Giulia, additional, Guarino, Maria, additional, Tagliavini, Simonetta, additional, D'Ambrosio, Federica, additional, Bristot, Laura, additional, Turco, Laura, additional, Rosato, Stefano, additional, Vella, Stefano, additional, Trenti, Tommaso, additional, Neri, Isabella, additional, La Marca, Antonio, additional, Manthena, Shivaji, additional, Goldstein, Andrea S., additional, Bruno, Savino, additional, Bao, Yanjun, additional, Gonzalez, Yuri Sanchez, additional, Villa, Erica, additional, Craxì, A., additional, Petta, S., additional, Calvaruso, V., additional, Brunetto, M., additional, Coco, B., additional, Chessa, L., additional, Pasetto, M.C., additional, Bigliotti, E., additional, Tamburrini, F., additional, Montalto, G., additional, Capitano, A.R., additional, Ieluzzi, D., additional, Fattovich, G., additional, Zignego, A.L., additional, Monti, M., additional, Gragnani, L., additional, Zuin, M., additional, Finati, E., additional, Giorgini, A., additional, Angarano, G., additional, Milella, M., additional, Alessandro, F., additional, Dallio, M., additional, Mazzella, G., additional, Lazzarini, G., additional, Di Fine, M., additional, Russo, F.P., additional, Zanetto, A., additional, Castelli, F., additional, Zaltron, S., additional, Raimondo, G., additional, Filomia, R., additional, Puoti, M., additional, Danieli, E., additional, Strazzabosco, M., additional, Gemma, M., additional, Angelico, M., additional, De Leonardis, F., additional, Gori, A., additional, Cappelletti, E., additional, Bruno, R., additional, Cima, S., additional, Coppola, C., additional, Amoruso, D.C., additional, Andreone, P., additional, Simonetti, G., additional, Gaeta, G.B., additional, Brancaccio, G., additional, Toniutto, P., additional, Dissegna, D., additional, Mondelli, M., additional, Ludovisi, S., additional, Persico, M., additional, Masarone, M., additional, Torti, C., additional, Strazzulla, A., additional, Rosina, F., additional, Framarin, L., additional, Weimer, L.E., additional, Quaranta, M.G., additional, Falzano, L., additional, and Mallano, A., additional

Published
2018
Full Text
View/download PDF

4. Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study

Author

Kondili, L., primary, Quaranta, M.G., additional, Falzano, L., additional, Di Gregorio, M., additional, Brunetto, M., additional, Zignego, A.L., additional, Ciancio, A., additional, Di Leo, A., additional, Rendina, M., additional, Raimondo, G., additional, Ferrari, C., additional, Craxì, A., additional, Taliani, G., additional, Borgia, G., additional, Gentile, I., additional, Santantonio, T.A., additional, Giammario, A., additional, Blanc, P., additional, Gaeta, G.B., additional, Gasbarrini, A., additional, Siciliano, M., additional, Chessa, L., additional, Erne, E.M., additional, Ieluzzi, D., additional, Russo, F.P., additional, Andreone, P., additional, Vinci, M., additional, Coppola, C., additional, Chemello, L., additional, Madonia, S., additional, Verucchi, G., additional, Persico, M., additional, Zuin, M., additional, Alberti, A., additional, Puoti, M., additional, Nardone, G., additional, De Maria, V., additional, Massari, M., additional, Montalto, G., additional, Foti, G., additional, Rumi, M.G., additional, Giacometti, A., additional, Benedetti, A., additional, D’Offizi, G., additional, Strazzabosco, M., additional, Fargion, S., additional, Angarano, G., additional, Federico, A., additional, Caporaso, N., additional, Mastroianni, C., additional, Toniutto, P., additional, Colombo, M., additional, Lazzarin, A., additional, Torti, C., additional, Andreoni, M., additional, Rosina, F., additional, Viscoli, C., additional, Vella, S., additional, and Villa, E., additional

Published
2016
Full Text
View/download PDF

5. HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Author

Kondili, L., primary, Weimer, L.E., additional, Mallano, A., additional, Fucili, L., additional, Massella, M., additional, Vinci, M., additional, Borgia, G., additional, Brunetto, M., additional, Surace, L., additional, Gaeta, G.B., additional, Chemello, L., additional, Andreone, P., additional, Raimondo, G., additional, Filomia, R., additional, Persico, M., additional, Puoti, M., additional, Rumi, M.G., additional, Benedetti, A., additional, Fargion, S., additional, Ieluzzi, D., additional, Nardone, G., additional, Giuseppe, F., additional, Ciancio, A., additional, Taliani, G., additional, Biliotti, E., additional, Madonia, S., additional, Stagno, B., additional, Alberti, A., additional, Massari, M., additional, Rosina, F., additional, Mazzella, G., additional, Di Leo, A., additional, Iannone, A., additional, Ferrari, C., additional, Orlandini, A., additional, Monti, M., additional, Santantonio, T.A., additional, Chessa, L., additional, Erne, E.M., additional, Coppola, C., additional, Andreoni, M., additional, Baldelli, F., additional, Mondelli, M., additional, Blanc, P., additional, Gasbarrini, A., additional, Verucchi, G., additional, Colombo, M., additional, Borghi, M., additional, Craxì, A., additional, Petta, S., additional, Villa, E., additional, Patti, O., additional, Russo, F.P., additional, Strazzabosco, M., additional, Vella, S., additional, and Zignego, A.L., additional

Published
2016
Full Text
View/download PDF

6. FRI-180 - Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study

Author

Kondili, L., Quaranta, M.G., Falzano, L., Di Gregorio, M., Brunetto, M., Zignego, A.L., Ciancio, A., Di Leo, A., Rendina, M., Raimondo, G., Ferrari, C., Craxì, A., Taliani, G., Borgia, G., Gentile, I., Santantonio, T.A., Giammario, A., Blanc, P., Gaeta, G.B., Gasbarrini, A., Siciliano, M., Chessa, L., Erne, E.M., Ieluzzi, D., Russo, F.P., Andreone, P., Vinci, M., Coppola, C., Chemello, L., Madonia, S., Verucchi, G., Persico, M., Zuin, M., Alberti, A., Puoti, M., Nardone, G., De Maria, V., Massari, M., Montalto, G., Foti, G., Rumi, M.G., Giacometti, A., Benedetti, A., D’Offizi, G., Strazzabosco, M., Fargion, S., Angarano, G., Federico, A., Caporaso, N., Mastroianni, C., Toniutto, P., Colombo, M., Lazzarin, A., Torti, C., Andreoni, M., Rosina, F., Viscoli, C., Vella, S., and Villa, E.

Published
2016
Full Text
View/download PDF

7. FRI-181 - HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Author

Kondili, L., Weimer, L.E., Mallano, A., Fucili, L., Massella, M., Vinci, M., Borgia, G., Brunetto, M., Surace, L., Gaeta, G.B., Chemello, L., Andreone, P., Raimondo, G., Filomia, R., Persico, M., Puoti, M., Rumi, M.G., Benedetti, A., Fargion, S., Ieluzzi, D., Nardone, G., Giuseppe, F., Ciancio, A., Taliani, G., Biliotti, E., Madonia, S., Stagno, B., Alberti, A., Massari, M., Rosina, F., Mazzella, G., Di Leo, A., Iannone, A., Ferrari, C., Orlandini, A., Monti, M., Santantonio, T.A., Chessa, L., Erne, E.M., Coppola, C., Andreoni, M., Baldelli, F., Mondelli, M., Blanc, P., Gasbarrini, A., Verucchi, G., Colombo, M., Borghi, M., Craxì, A., Petta, S., Villa, E., Patti, O., Russo, F.P., Strazzabosco, M., Vella, S., and Zignego, A.L.

Published
2016
Full Text
View/download PDF

26. Liver transplant for viral hepatitis

Author

Smedile, A., primary, Marzano, A., additional, Farci, P., additional, Chiaberge, E., additional, Abate, M., additional, Ottobrelli, A., additional, Brunetto, M.R., additional, Rosina, F., additional, Durazzo, M., additional, Verme, G., additional, Bonino, F., additional, and Rizzetto, M., additional

Published
1991
Full Text
View/download PDF

28. Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection

Author

Salassa, B., primary, Daziano, Enrica, additional, Bonino, F., additional, Lavarini, Carla, additional, Smedile, Antonina, additional, Chiaberge, Elisabetta, additional, Rosina, F., additional, Brunetto, Maurizia Rossana, additional, Pessione, Enrica, additional, Spezia, C., additional, Bramato, C., additional, and Soranzo, Maria Luisa, additional

Published
1991
Full Text
View/download PDF

29. Autoantibodies and response to α-interferon in patients with chronic viral hepatitis

Author

Saracco, G., primary, Touscoz, A., additional, Durazzo, M., additional, Rosina, F., additional, Donegani, E., additional, Chiandussi, L., additional, Gallo, V., additional, Petrino, R., additional, De Micheli, A.G., additional, Solinas, A., additional, Deplano, A., additional, Tocco, A., additional, Cossu, P.A., additional, Pintus, C., additional, Verme, G., additional, and Rizzetto, M., additional

Published
1990
Full Text
View/download PDF

31. Treatment with interferon alfa-2b of chronic HDV hepatitis in children

Author

Craxi, A, primary, Di Marco, V, additional, Volpes, R, additional, Marra, S, additional, Rizzetto, M, additional, Rosina, F, additional, Barbera, C, additional, Bortolotti, F, additional, Crivellaro, C, additional, Iannuzzi, C, additional, Calzia, R, additional, Giacchino, R, additional, Timitilli, A, additional, Vajro, P, additional, Fontanella, A, additional, and Pintus, C, additional

Published
1990
Full Text
View/download PDF

32. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

Author

Saracco, G., primary, Rosina, F., additional, Cerenzia, M.R.Torrani, additional, Lattore, V., additional, Chiandussi, L., additional, Gallo, V., additional, Petrino, R., additional, De Micheli, A.G., additional, Donegani, E., additional, Solinas, A., additional, Deplano, A., additional, Tocco, A., additional, Cossu, P., additional, Pintus, C., additional, David, E., additional, Mazzucco, G., additional, Verme, G., additional, and Rizzetto, M., additional

Published
1990
Full Text
View/download PDF

35. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection

Author

Saracco, Giorgio Maria, Rosina, F., Brunetto, Mr, Amoroso, P., Caredda, F., Farci, P., Piantino, P., Bonino, F., and Rizzetto, Mario

Subjects
Adult, Liver Cirrhosis, Male, Hepatitis B Surface Antigens, Time Factors, Adolescent, Italy, Liver, Humans, Longitudinal Studies, Hepatitis B, Hepatitis B Core Antigens, Hepatitis D
Abstract

Serum or liver markers of hepatitis delta virus (HDV) infection were found in 20 of 22 (90%) Italian patients presenting with an ostensible type B hepatitis that ran an accelerated course to cirrhosis. The features of the illness conformed to a syndrome of HDV infection in young males carrying the hepatitis B surface antigen (HBsAg); a latent HBsAg state was documented in many patients by a history of prior exposure to the hepatitis B virus (HBV) or by the absence of IgM antibodies to the HB core antigen. Characteristic of the disease were the clinical overture as a severe hepatitis, the lobular involvement by an extensive necroinflammatory reaction, the exuberant expression of intrahepatic hepatitis delta antigen and an atypical HBV profile of inactive infection or accelerated seroconversion from HBeAg to anti-HBe. Superimposed upon HBV infection, HDV may create a rapidly progressive course which resembles very aggressive hepatitis B but is infrequently observed in hepatitis B alone.

Published
1987

39. Antibody to hepatitis C virus in the serum of patients with chponic hepatitis

Author

Bonino, F., primary, Kuo, G., additional, Brunetto, M.R., additional, Saracco, G., additional, Rosina, F., additional, Oliveri, F., additional, Baldi, M., additional, Vallauri, P., additional, Torrani Cerenzia, M., additional, Capaibo, M., additional, Rizzetto, M., additional, Verme, G., additional, Choo, O.L., additional, and Hougbton, M., additional

Published
1989
Full Text
View/download PDF

40. Treatment of chronic delta hepatitis with α-2 recombinant interferon

Author

Rizzetto, M., primary, Rosina, F., additional, Saracco, G., additional, Bellando, P.C., additional, Actis, G.C., additional, Bonino, F., additional, Smedile, A., additional, Trinchero, P., additional, Sansalvadore, F., additional, Pintus, C., additional, Dianzani, F., additional, and Verme, G., additional

Published
1986
Full Text
View/download PDF

47. Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?

Author

Sansoè G, Aragno M, Mastrocola R, Restivo F, Mengozzi G, Smedile A, Rosina F, Danni O, Parola M, and Rizzetto M

Subjects
Animals, Arginine Vasopressin metabolism, Atrial Natriuretic Factor metabolism, Blood Pressure drug effects, Blood Pressure physiology, Carbon Tetrachloride toxicity, Cyclic GMP metabolism, Cyclohexanecarboxylic Acids metabolism, Cyclohexanecarboxylic Acids pharmacology, Cyclohexanecarboxylic Acids therapeutic use, Cytokines metabolism, Endothelin-1 metabolism, Humans, Liver cytology, Liver enzymology, Liver Cirrhosis, Experimental chemically induced, Male, Portal Vein drug effects, Portal Vein physiology, Protease Inhibitors metabolism, Protease Inhibitors therapeutic use, Rats, Rats, Wistar, Vascular Resistance drug effects, Hypertension, Portal drug therapy, Liver Cirrhosis, Experimental enzymology, Neprilysin antagonists & inhibitors, Neprilysin metabolism, Vascular Resistance physiology
Abstract

Background/aims: In liver cirrhosis atrial natriuretic peptide (ANP) decreases portal vascular resistance and tributary flow. The enzyme neutral endopeptidase (NEP) degrades ANP and bradykinin and generates endothelin-1 from big-endothelin. We determined the effects of NEP inhibition by candoxatrilat on hormonal status, liver function and arterial and portal pressures in rats with CCl4-induced cirrhosis., Methods: Two groups of seven control rats received 1 ml 5% glucose solution alone or containing 10 mg/kg candoxatrilat; three groups of 10 ascitic cirrhotic rats received placebo, 5 or 10 mg/kg candoxatrilat. NEP protein concentration and immunostaining were analyzed in normal and cirrhotic livers., Results: In cirrhotic rats 10 mg/kg candoxatrilat significantly increased steady-state indocyanine green clearance (a parameter reflecting liver plasma flow) (P<0.01), decreased portal pressure (P<0.01), had no effect on arterial pressure and plasma renin activity but increased ANP plasma levels (P<0.05) and urinary excretions (P<0.01) of ANP and cGMP. In the cytosol fraction of rat cirrhotic livers a 280% increase in NEP content was found (P<0.01), chiefly localized in desmin-positive myofibroblast-like cells of fibrous septa., Conclusions: Candoxatrilat has few effects on systemic hemodynamics and hormonal status; its portal hypotensive action depends on effects exerted on intrahepatic vascular resistance.

Published
2005
Full Text
View/download PDF

48. Inappropriately low angiotensin II generation: a factor determining reduced kidney function and survival in patients with decompensated cirrhosis.

Author

Sansoé G, Silvano S, Mengozzi G, Todros L, Smedile A, Touscoz G, Rosina F, and Rizzetto M

Subjects
Adult, Aged, Aged, 80 and over, Angiotensin II blood, Angiotensinogen blood, Blood Volume, Case-Control Studies, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Liver physiopathology, Liver Cirrhosis blood, Liver Cirrhosis metabolism, Male, Middle Aged, Peptidyl-Dipeptidase A blood, Prospective Studies, Renal Circulation, Renin blood, Survival Analysis, Angiotensin II biosynthesis, Kidney physiopathology, Liver Cirrhosis physiopathology
Abstract

Background/aims: Angiotensin II contributes to the post-glomerular arteriolar vasoconstriction which maintains the glomerular filtration rate (GFR) in renal hypoperfusion. To explore whether depressed angiotensin II generation, due to reduced angiotensinogen production or low angiotensin-converting enzyme (ACE) levels, could impair kidney function in advanced cirrhosis., Methods: We studied and prospectively followed up 21 diuretic-free ascitic cirrhotic patients, through these determinations: plasma levels of active renin (AR), renin activity (PRA), angiotensin II, ACE and aldosterone; renal clearances of sodium, inulin and para-aminohippurate; antipyrine clearance. Fifteen healthy subjects were also studied., Results: GFR distribution was bimodal, 10 patients had low GFR values (l-GFR group) and 11 had normal-GFR values (n-GFR group) (below and above 105 ml/min per 1.73 m(2) body surface area). Antipyrine clearance and Child-Pugh score did not differ in the two patient groups. l-GFR group had higher AR and PRA values, lower ACE levels and a significantly higher AR/Angiotensin II ratio than n-GFR group (all P<0.01). All 21 patients showed increased values of the AR/PRA ratio, i.e. subnormal angiotensinogen levels (P<0.03). The 18-month survival rates of l-GFR and n-GFR groups were 20 and 81% (P<0.02)., Conclusions: Low-GFR cirrhotic patients had a worse survival rate associated with more severe contraction of the effective arterial blood volume, higher AR/Angiotensin II ratio and lower ACE levels.

Published
2004
Full Text
View/download PDF

49. Rabbit-derived anti-HD antibodies for HDAg immunoblotting.

Author

Rosina F, Fabiano A, Garripoli A, Smedile A, Mattalia A, Eckart MR, Houghton M, and Bonino F

Subjects
Animals, Antigens, Viral immunology, Electrophoresis, Polyacrylamide Gel, Hepatitis B Surface Antigens analysis, Hepatitis delta Antigens, Humans, Immunoblotting methods, Liver pathology, Molecular Weight, Rabbits immunology, Antibodies isolation & purification, Antigens, Viral analysis, Hepatitis D diagnosis, Liver microbiology, Liver Transplantation pathology
Abstract

We studied the sensitivity and specificity of two rabbit-derived antibodies (W2 and W3) raised against two synthetic peptides of the HDAg: the C-terminus of the p24 protein (W2) and the C-terminus of the p27 protein (W3) (Chiron Co., Emeryville, CA, U.S.A.). The results were compared with those obtained with a human polyclonal anti-HD (W1). We have tested W2 and W3 against blotted serum samples from 25 patients (20 HBsAg positive anti-HD positive, three HBsAg positive anti-HD negative and two HBsAg negative anti-HD negative) and liver extracts from five HBsAg seropositive patients, two anti-HD positive and three anti-HD negative. In serum samples W3 sporadically reacted with a p31 protein present in both anti-HD positive and negative sera; W2 identified the p24 protein in 7/10 W1 positive samples but in none of 10 W1 negative; the p27 protein was captured by W2 only in one highly viremic serum. In every sample of liver extract W3 recognized a 48-kDa band. W1 and W2 stained 5 bands at 45, 27, 24, 16 and 12 kDa. The p45, p27 and p24 proteins were peculiar of HDV-infected livers; p16 and p12 were also detected in HDV free livers. W2 identified an additional 54-kDa protein in 4/5 liver extracts. For diagnostic purposes human polyclonal anti-HD represents the most sensitive probe for HDAg immunoblotting, with a specificity similar to that of rabbit-derived antibodies. The affinity of W2 and W3 antibodies for serum and liver HDAg appears to be lower than for HDAg recombinant.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1991
Full Text
View/download PDF

50. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis.

Author

Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, Gallo V, Petrino R, De Micheli AG, and Solinas A

Subjects
Animals, Chronic Disease, Fluorescent Antibody Technique, Hepatitis B drug therapy, Hepatitis B epidemiology, Hepatitis B immunology, Hepatitis C drug therapy, Hepatitis C epidemiology, Hepatitis C immunology, Hepatitis D drug therapy, Hepatitis D epidemiology, Hepatitis D immunology, Hepatitis, Viral, Human epidemiology, Hepatitis, Viral, Human immunology, Humans, Interferon Type I immunology, Italy epidemiology, Mice, Prospective Studies, Rats, Autoantibodies immunology, Hepatitis, Viral, Human drug therapy, Interferon Type I therapeutic use
Abstract

One hundred and fifteen patients with chronic type B, D and non-A, non-B hepatitis treated with recombinant alpha-interferon were tested for six different autoantibodies prior to or during therapy, and the course of treatment was compared in autoantibody-positive and -negative patients. Three out of 25 (12%) hepatitis B patients, 14 out of 30 (47%) hepatitis D patients and 19 out of 60 (32%) chronic non-A, non-B hepatitis carriers had baseline or post-therapy autoantibodies. The rate of response between patients with and without autoantibodies among B, D and non-A, non-B patients was, respectively, 67 vs. 79%, 23 vs. 25%, 70 vs. 61% (p = N.S.). No adverse reaction was observed in the 36 patients who had or developed nuclear, smooth muscle, parietal cells and thyroid autoantibodies during therapy. A patient with baseline antibodies against liver and kidney microsomes developed an icteric acute hepatitis at the fourth month of therapy, but five other patients with this reactivity responded to therapy uneventfully. The presence of autoantibodies before therapy or their induction following therapy is not a contraindication to the use of interferon in patients with chronic viral hepatitis.

Published
1990
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results